Acute Ischemic Cerebrovascular Disease
Conditions
Brief summary
Clinical studies applying ozonated autohemotherapy to treat acute cerebrovascular diseases have validated the safety and efficacy of this treatment, as well as explored its mechanism of action.
Interventions
PROCEDUREOxygen
Oxygen and standard therapy were given
PROCEDUREOzone
Ozone and standard therapy were given
PROCEDUREStandard therapy
Best standard of care
Sponsors
The First Affiliated Hospital of Zhengzhou University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Confirmed by cranial CT or MRI examination, first-ever stroke, hospital admission within \<24 hours of symptom onset, 2. age \>18 years, 3. NIHSS score between 4 and 15, 4. TOAST classification as large artery atherosclerosis, 5. complete clinical records, minimum follow-up period of ≥3 months post-discharge, 6. willingness to undergo brachial blood puncture treatment, and provision of informed consent
Exclusion criteria
1. other neurological disorders, cerebral infarction caused by vertebral-basilar artery disease, cardioembolic stroke, or large-vessel vasculitis, acute or chronic infectious diseases, autoimmune or hematologic disorders, malignant tumors, mental abnormalities, severe heart, liver, or kidney dysfunction, intracerebral hemorrhage, and craniocerebral surgery history. 2. Contraindications for ozone therapy included hyperthyroidism, favism, severe coagulation disorders, and abnormal puncture site barriers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The expression of SOD(Superoxide dismutase) | 7 days |
Countries
China
Outcome results
None listed